Back to Top

FOR SOME PATIENTS

Uncontrolled Gout Can Go On and On and On

Whether you call it severe gout, chronic gout, tophaceous gout, or uncontrolled gout, the challenges your patients are facing with persistently high serum uric acid (sUA) levels go beyond the flares and tophi. This systemic, progressive disease can have a debilitating impact on the person.1-6

See the Full Impact

mobile campaign image

What Is Uncontrolled Gout?

Uncontrolled gout is defined as persistent, sustained sUA levels of >6 mg/dL despite urate-lowering treatment. Indicators of uncontrolled gout include1,5:

Recurrent gout flares icon

2 or more
recurrent flares
a year

Visible tophi icon

Visible, non-resolving tophi that are painful and may lead to bone erosion and joint deformity

The likelihood of tophi increases over time. In one 12-month analysis, >60% of patients with uncontrolled gout had tophi5*

*Based on a retrospective, observational study of a longitudinal, commercial, health-plan database that included patients with a pegloticase claim (index date) and continuous enrollment in the prior 24 months. The featured percentage is from the 12-month period prior to the index date.5

Some contributing factors in uncontrolled gout can include7-10:

Gout genetics icon

Genetics

There are more than 12 identified genetic variants that predispose
people to developing gout7

Dysbiosis icon

Dysbiosis

Can affect purine metabolism and uric acid excretion and promote the release of inflammatory mediators, contributing to sustained sUA and the likelihood of a flare8,9

Gout diet icon

Diet

Dietary patterns are noted as factors in elevated urate levels, with modifications able to reduce sUA by 1 to 2 mg/dL10

Uncontrolled chronic gout prevalence in the US

It is estimated that uncontrolled gout affects

~170,000 people in the United States.11-14†

†The number of uncontrolled gout patients was estimated by applying the rate of uncontrolled gout patients to the total gout population in 2024. Total gout population derived from the 2015-2016 National Health and Nutrition Examination Survey (NHANES) patient-reported gout prevalence survey adjusted for over-reporting and population growth. Rate of uncontrolled gout patients derived from Intercontinental Medical Statistics (IMS) Health and Quintiles (IQVIA) Longitudinal Access and Adjudication Data (LAAD) Claims.11-14

Updates icon

Sign Up for Updates

Be the first to know about our updates in uncontrolled gout.

Sign Up Now

References

1. Francis-Sedlak M, et al. Rheumatol Ther. 2021;8(1):183-197. 2. Brook RA, et al. Curr Med Res Opin. 2010;26(12):2813-2821. 3. Dalbeth N, et al. Lancet. 2021;397(10287):1843-1855. 4. Perez-Ruiz F, et al. Ann Rheum Dis. 2014;73(1):177-182. 5. Morlock RJ, et al. Rheumatol Ther. 2025;12(1):37-51. 6. Timsans J, et al. J Clin Med. 2024;13(24):7616. 7. Reginato AM, et al. Nat Rev Rheumatol. 2012;8(10):610-621. 8. Tong S, et al. Front Cell Infect Microbiol. 2022;12:1051682. 9. Shirvani-Rad S, et al. Front Med (Lausanne). 2023;10:1163778. 10. Fenando A, et al. Gout. In: StatPearls. StatPearls Publishing; February 12, 2024. https://www.ncbi.nlm.nih.gov/books/NBK546606/ 11. Chen-Xu M, et al. Arthritis Rheumatol. 2019;71(6):991-999. 12. GBD 2021 Gout Collaborators. Lancet Rheumatol. 2024;6:e507-517. 13. Sobi data on file. 14. McAdams MA, et al. J Rheumatol. 2011:38(1):135-141.